Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GANAB | Q14697 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27816064 | 1.00 | SLC18A3 (0.41) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL2300746 | 0.81 | — | — | |
| SCHEMBL1404038 | 0.74 | SLC18A3 (0.44) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL2801018 | 0.72 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL6519582 | 0.72 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL1404005 | 0.72 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL3391750 | 0.72 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL19468663 | 0.72 | — | — | |
| SCHEMBL7328433 | 0.72 | SLC18A3 (0.38) | SLC18A3 | |
| SCHEMBL1845216 | 0.72 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-212119073-U | Vacuum distillation device for solicin raw material medicine | 南京美瑞制药有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-104496981-B | 2,2-dithienyl-2-hydroxycaproic acid-R-quinine-3-ester compound and preparation method thereof | 东华大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-104478871-B | A kind of choline m receptor antagonist aclidinium bromide and preparation method thereof | 东华大学 | 2016-09-07 | — | — | CN | disclosed |
| CN-104496981-A | 2,2-dithienyl-2-hydroxycaproic acid-R-quinine-3-ester compound and preparation method thereof | NAT UNIV DONG HWA | 2015-04-08 | — | — | CN | disclosed |
| CN-104478871-A | Choline M receptor antagonist aclidinium bromide and preparation method thereof | NAT UNIV DONG HWA | 2015-04-01 | — | — | CN | disclosed |
| US-7183323-B2 | Diaromatic compound containing 2-amine groups, useful for treating neuropathic pain | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040204460-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-10-14 | — | — | US | disclosed |
| US-6756400-B2 | Sodium channel modulators | THERAVANCE, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030027822-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-02-06 | — | — | US | disclosed |
| WO-2002018334-A2 | SODIUM CHANNEL MODULATORS | THERAVANCE, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204460-A1 | Sodium channel modulators | SCN1A, SCN1B, CACNA1A | SLC18A3 748/4885PKM 3952/4885GAA 3757/4885 |
| US-20030027822-A1 | Sodium channel modulators | SCN1A, SCN1B, CACNA1A | SLC18A3 748/4885PKM 3952/4885GAA 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.